title: Clinical applications of the sustained-release dexamethasone implant for treatment of macular edema.
abstract: Macular edema is one of the leading causes of vision loss among patients with retinal vein occlusion, diabetic retinopathy, and posterior chamber inflammatory disease. However, the treatment of macular edema is considerably limited by the difficulty in delivering effective doses of therapeutic agents into the vitreous cavity. In recent years, the development of a sustained-release dexamethasone intravitreal implant (Ozurdex(®)) has enabled more controlled drug release at a stable rate over a long period of time, with a potentially lower rate of adverse events. Clinical studies indicate that this dexamethasone implant is a promising new treatment option for patients with persistent macular edema resulting from retinal vein occlusion, diabetic retinopathy, and uveitis or Irvine-Gass syndrome.
authors.affiliation: Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, Complutense University, Madrid, Spain;
authors.forename: Rocío
authors.initials: R
authors.lastname: Herrero-Vanrell
authors.forename: Jose Augusto
authors.initials: JA
authors.lastname: Cardillo
authors.forename: Baruch D
authors.initials: BD
authors.lastname: Kuppermann